Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma

Int J Dermatol. 2011 Aug;50(8):1006-13. doi: 10.1111/j.1365-4632.2010.04843.x.

Abstract

Background: Recently, ultraviolet (UV) A1 phototherapy has been suggested as an effective treatment for localized scleroderma (LS); however, the optimal dose of UVA1 still has not been determined.

Objective: We aimed to evaluate the therapeutic effectiveness of medium-dose (30 J/cm(2) ) UVA1 phototherapy and to show that 13MHz ultrasound is a valuable tool for assessing the results of UVA1 phototherapy in LS.

Methods: Thirty-five patients with LS were treated with medium-dose (30J/cm(2) ) UVA1. In total, 30-45 treatments and 900-1350J/cm(2) cumulative UVA1 doses were evaluated by clinical scoring in all patients. In 14 patients, skin thickness was also determined by 13MHz ultrasound examination.

Results: In all patients, medium-dose UVA1 therapy softened sclerotic plaques, and marked clinical improvement was observed in 29 of 35 (82. 85%) patients. Ultrasound measurements showed that skin thickness was significantly reduced. No side effects were observed during or after treatment.

Conclusion: Medium-dose UVA1 phototherapy is a highly effective, safe, and well-tolerated therapeutic modality for treatment of all types of LS. A 13MHz ultrasound probe may be used for evaluating UVA1 phototherapy results.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Biopsy
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Scleroderma, Localized / diagnostic imaging
  • Scleroderma, Localized / pathology
  • Scleroderma, Localized / radiotherapy*
  • Skin / pathology
  • Skin / radiation effects
  • Treatment Outcome
  • Ultrasonography
  • Ultraviolet Therapy / methods*
  • Young Adult